Laxmi Organic Industries (LXCHEM) investor relations material

Executive summary

• Delivered strong Q1 FY 2027 results with broad-based growth, driven by both volume and price increases across the portfolio despite global volatility and supply chain disruptions.

• Successfully navigated raw material price spikes, logistics challenges, and maintained supply chain agility, ensuring business continuity.

• Successfully commissioned new ethyl acetate capacity and completed scheduled maintenance at Mahad Site I.

• Unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, were approved and reviewed by the Board and auditors.

• Dahej project progressing well, with phase II mechanical completion expected in Q3 and revenue ramp-up in FY 2028.

Financial highlights

• Q1 FY 2027 consolidated revenue reached INR 9,683 million, up 40% year-over-year and 32% sequentially.

• EBITDA for the quarter was INR 1,143 million, up 272% year-over-year, with margin expanding 660 bps to 37.5%.

• PAT grew 216% year-over-year to INR 677 million, with PAT margin up 390 bps to 7.0%.

• Specialty business revenue at INR 2,418 million (17% YoY, 13% QoQ growth); essentials at INR 7,265 million (50% YoY, 39% QoQ growth).

• Volume growth contributed ~10% to revenue increase, with the remainder from price and product mix.

Outlook and guidance

• Essentials business expected to deliver mid-single digit EBITDA margins over the cycle, with recent quarters showing 11%-12%.

• Specialty business ramp-up to continue, with positive momentum anticipated as new capacities come online.

• Dahej phase II to be capitalized in Q2, with revenue contribution expected from FY 2028.

• Full-year CapEx guidance between INR 125-150 crore, including Dahej.

• Tax expense for the quarter is not comparable to previous periods due to a change in tax regime and utilization of brought forward losses.